Back to search
Non-Active Secondary Progressive Multiple Sclerosis
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Non-Active Secondary Progressive Multiple Sclerosis trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Non-Active Secondary Progressive Multiple Sclerosis trials you may qualify forOrelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and saf…
Foralumab is a human anti-CD3 monoclonal antibody being developed for the treatment of autoimmune and inflammatory diseases. The goal of this Phase 2a, randomi…
Only subjects that have completed TILS-021, a Phase 2a Randomized, Double-Blind, Placebo-Controlled, Multicenter Dose-Ranging Study of Nasal Foralumab in Non-Ac…
The purpose of the study is to evaluate the efficacy and safety of subcutaneously administered cladribine versus placebo to stop inflammation and treat disease…
To evaluate the efficacy and safety of oral masitinib versus placebo in the treatment of patients with primary progressive or secondary progressive multiple scl…
This is an observational, multicenter, single-arm, prospective study conducted in Italy
The DanNORMS study is a phase 3, non-inferiority clinical trial examining whether treatment of active multiple sclerosis with rituximab is non-inferior to ocrel…